Skip to main content

Key Product Details

Species Reactivity

Validated:

Mouse

Cited:

Human, Mouse

Applications

Validated:

Western Blot

Cited:

Immunohistochemistry-Paraffin, Western Blot, Immunoprecipitation

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse Fetuin A/AHSG (R&D Systems, Catalog # 1563-PI)
Ala19-Ile345
Accession # NP_038493

Specificity

Detects mouse Fetuin A/AHSG in direct ELISAs and Western blots. In these formats, approximately 5% cross-reactivity with recombinant human Fetuin A/AHSG is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Mouse Fetuin A/AHSG Antibody

Detection of Fetuin A/AHSG by Western Blot

Detection of Fetuin A/AHSG by Western Blot

Activation of AMPK downregulates high glucose-induced Fet-A expression in HepG2 cells.[A] HepG2 cells were incubated in a media containing either mannitol, low glucose or high glucose for 12 hours, and cell lysates/media were subjected to immunoblotting for Fet-A and pFet-A (n = 3). [B] HepG2 cells were incubated with either low- or high-glucose in the absence or presence of AICAR for 12 h and cell lysates were analyzed by Western blotting. The blots were analyzed with antibodies against Fet-A (n = 4). [C] HepG2 cells were incubated with increasing concentrations (0.5, 1, 2 mM) of AICAR for 12 h. Cell lysate or media were analyzed by Western blotting for indicated proteins (n = 3) and [D] level of Fet-A and pFet-A in media, as a ratio of GAPDH were expressed. [E] HepG2 cells were incubated in low or high glucose in the absence or presence of AICAR/metformin for 12 hours, and media was used to detect Fet-A by ELISA technique (n = 4). [F] Real-time gene expression analysis was carried out for Fet-A after AICAR and metformin treatment (n = 4). [G] HepG2 cells were incubated with AICAR/metformin in the presence or absence of Compound C, an AMPK inhibitor. Cell lysates were immunoblotted for pAMPK, Fet-A as well as p-Fet-A and [H] Fet-A levels, as a ratio to GAPDH are depicted (n = 4). Data are shown as Means ± SEM. P values were determined by one-way ANOVA followed by Tukey’s multiple comparison tests (C-F). Data are representative of at least three independent experiments performed in replicates. * Indicates p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35522655), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Fetuin A/AHSG by Western Blot

Detection of Fetuin A/AHSG by Western Blot

Activation of AMPK downregulates high glucose-induced Fet-A expression in HepG2 cells.[A] HepG2 cells were incubated in a media containing either mannitol, low glucose or high glucose for 12 hours, and cell lysates/media were subjected to immunoblotting for Fet-A and pFet-A (n = 3). [B] HepG2 cells were incubated with either low- or high-glucose in the absence or presence of AICAR for 12 h and cell lysates were analyzed by Western blotting. The blots were analyzed with antibodies against Fet-A (n = 4). [C] HepG2 cells were incubated with increasing concentrations (0.5, 1, 2 mM) of AICAR for 12 h. Cell lysate or media were analyzed by Western blotting for indicated proteins (n = 3) and [D] level of Fet-A and pFet-A in media, as a ratio of GAPDH were expressed. [E] HepG2 cells were incubated in low or high glucose in the absence or presence of AICAR/metformin for 12 hours, and media was used to detect Fet-A by ELISA technique (n = 4). [F] Real-time gene expression analysis was carried out for Fet-A after AICAR and metformin treatment (n = 4). [G] HepG2 cells were incubated with AICAR/metformin in the presence or absence of Compound C, an AMPK inhibitor. Cell lysates were immunoblotted for pAMPK, Fet-A as well as p-Fet-A and [H] Fet-A levels, as a ratio to GAPDH are depicted (n = 4). Data are shown as Means ± SEM. P values were determined by one-way ANOVA followed by Tukey’s multiple comparison tests (C-F). Data are representative of at least three independent experiments performed in replicates. * Indicates p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35522655), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Fetuin A/AHSG by Western Blot

Detection of Fetuin A/AHSG by Western Blot

Activation of AMPK downregulates high glucose-induced Fet-A expression in HepG2 cells.[A] HepG2 cells were incubated in a media containing either mannitol, low glucose or high glucose for 12 hours, and cell lysates/media were subjected to immunoblotting for Fet-A and pFet-A (n = 3). [B] HepG2 cells were incubated with either low- or high-glucose in the absence or presence of AICAR for 12 h and cell lysates were analyzed by Western blotting. The blots were analyzed with antibodies against Fet-A (n = 4). [C] HepG2 cells were incubated with increasing concentrations (0.5, 1, 2 mM) of AICAR for 12 h. Cell lysate or media were analyzed by Western blotting for indicated proteins (n = 3) and [D] level of Fet-A and pFet-A in media, as a ratio of GAPDH were expressed. [E] HepG2 cells were incubated in low or high glucose in the absence or presence of AICAR/metformin for 12 hours, and media was used to detect Fet-A by ELISA technique (n = 4). [F] Real-time gene expression analysis was carried out for Fet-A after AICAR and metformin treatment (n = 4). [G] HepG2 cells were incubated with AICAR/metformin in the presence or absence of Compound C, an AMPK inhibitor. Cell lysates were immunoblotted for pAMPK, Fet-A as well as p-Fet-A and [H] Fet-A levels, as a ratio to GAPDH are depicted (n = 4). Data are shown as Means ± SEM. P values were determined by one-way ANOVA followed by Tukey’s multiple comparison tests (C-F). Data are representative of at least three independent experiments performed in replicates. * Indicates p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35522655), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Mouse Fetuin A/AHSG Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse Fetuin A/AHSG (Catalog # 1563-PI)

Reviewed Applications

Read 1 review rated 5 using AF1563 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Fetuin A/AHSG

Mouse Fetuin A, also known as alpha2-Heremans-Schmid glycoprotein, is encoded by the AHSG gene. It has been also called "countertrypsin" because of its ability to inhibit trypsin (1). It is a major plasma protein and a member of the cystatin superfamily of protease inhibitors (2, 3). It is expressed by hepatocytes, the principal cell source, and by monocyte/macrophages (4). The major form of plasma Fetuin A corresponds to two disulfide bond-linked chains derived from the single chain (5). Fetuin-A has a number of functions. It is a negative acute-phase protein with normal circulating levels in adults (300-600 μg/mL), which fall significantly (30-50%) during injury and infection (5). It enhances entry of cationic inhibitors into macrophages (6). It inhibits both insulin receptor autophosphorylation and undesirable calcification (7, 8).

References

  1. Yamamoto, K. and H. Sinohara (1993) J. Biol. Chem. 268:17750.
  2. Kellemann, J. et al. (1989) J. Biol. Chem. 264:14121.
  3. Dziegielewska, K.M. et al. (1990) J. Biol. Chem. 265:4354.
  4. Dziegielewska, K.M. et al. (1996) Histochem. Cell Biol. 106:319.
  5. Gejyo, F. and K. Schmid (1981) Biochim. Biophys. Acta 671:78.
  6. Wang, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:14429.
  7. Mathews, S.T. et al. (2000) Mol. Cell Endocrinol. 164:87.
  8. Schäfer, C. et al. (2003) J. Clin. Invest. 112:357.

Long Name

alpha-2-HS Glycoprotein

Alternate Names

AHSG, alpha-2-HS-glycoprotein

Entrez Gene IDs

197 (Human); 11625 (Mouse); 25373 (Rat)

Gene Symbol

AHSG

UniProt

Additional Fetuin A/AHSG Products

Product Documents for Mouse Fetuin A/AHSG Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse Fetuin A/AHSG Antibody

For research use only

Loading...
Loading...
Loading...
Loading...